A Pilot Study of Genasense (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia.

Trial Profile

A Pilot Study of Genasense (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2011

At a glance

  • Drugs Fludarabine; Oblimersen; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genta (CEASED)
  • Most Recent Events

    • 04 Nov 2011 Planned end date changed from 1 Sep 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Planned end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top